Objectives-Apoptotic monocytes release membrane microparticles which may play a major role in thrombogenicity through a P-selectin glycoprotein ligand (PGSL-1)-mediated mechanism. We have studied systematically the regulation of PSGL-1 expression and function in apoptotic monocytic cells.
T he cell adhesion molecules P-selectin glycoprotein ligand (PSGL-1) and its receptor P-selectin (CD62P) are important mediators in the primary interaction between leukocytes and both endothelial cells and activated platelets. 1 PSGL-1-P-selectin interaction has been also recognized as a crucial event in the incorporation into growing thrombi of tissue factor-containing microparticles. 2 PSGL-1 expression was long considered unregulated. Evidence has emerged, however, to link a reduction of cell surface PSGL-1 expression to stimulation of leukocytes. 3, 4 An upregulation of PSGL-1 on leukocytes from patients with chronic obstructive pulmonary disease was also observed. 5 Recent data demonstrate that PSGL-1 surface expression may be decreased in apoptotic monocytic cells. 6 We have, therefore, studied systematically the effects of apoptosis on PSGL-1 expression in function in monocytes.
Materials and Methods

Cell Systems and Transfection
U937 cells, human umbilical vein endothelial cells (HUVECs; kindly provided by Dr U. Rauch, Charité, Berlin, Germany), immortalized ADAM-10 Ϫ/Ϫ and -17 Ϫ/Ϫ MEFs (kindly provided by Drs P. Saftig and S. Rose-John, University of Kiel, Germany), and HEK293 cells were used. Human monocytes and platelets were isolated from citrated blood. A human PSGL-1 cDNA clone was kindly provided by Dr D. Vestweber (University of Münster, Germany). MEFs were transfected using Optifect transfection reagent (Qiagen). For siRNA experiments, HEK293 cells were cotransfected with PSGL-1 cDNA and with ADAM-8 or ADAM-9 siRNA using the DharmaFECT 1 siRNA Transfection Reagent.
Flow Cytometry
PSGL-1 expression was quantified using anti-PSGL-1-PE antibodies. Annexin-V-PE binding was measured using EDTA as a negative control. Monocyte-platelet aggregates were detected using anti-CD61-fluorescein isothiocyanate (FITC) antibodies and gating of monocytes on CD45-PE.
Immunofluorescence Microscopy, Immunoblotting, and Zymography
Methanol-fixed cells were stained with anti-PSGL-1 antibodies and Cy3-conjugated secondary antibodies. Protein expression was also determined by SDS-PAGE/Western blotting. Zymography was performed using SDS/polyacrylamide gels, containing gelatin. 
Quantitative RT-PCR
Perfusion Experiments
Parallel flow chamber perfusion experiments were performed at a shear rate of 125 s Ϫ1 using confluent HUVECs and calcein-AMlabeled U937 cells. For details, see the supplemental materials (available online at http://atvb.ahajournals.org).
Results
Staurosporine, dactinomycine, and etoposid led to an almost complete downmodulation of PSGL-1 surface expression in U937 cells and in human blood monocytes, whereas cell activation resulted in a modest reduction of PSGL-1 ( Figure 1A and 1B) . The kinetics of PSGL-1 reduction was nearly indentical with the occurrence of apoptosis markers, (Figure 2C through 2F) and was prevented by VAD fmk, indicating an apoptosis-related mechanism. Downmodulation of PSGL-1 was confirmed by Western blotting and immunofluorescence microscopy ( Figure 1G and 1H) . A marked reduction of PSGL-1 mRNA was also observed. However, because PSGL-1 was found to be a long-living protein, transcriptional downregulation is unlikely to account for the complete loss of the protein. Ultracentrifugation pellets and supernatants of conditioned media were examined to discriminate soluble from microparticle-bound PSGL-1 fragments. Staurosporine reduced whereas PMA increased microparticle PSGL-1 expression, the latter possibly reflecting the occurrence of a proteolytic fragment (Figure 2A and 2B) . PE-conjugated anti-PSGL-1 antibodies were released from the cell surface on apotosis induction ( Figure 2C) , indicating a proteolytical shedding. Systematic screening of protease inhibitors combined with knock-out and siRNA experiments characterized the PSGL-1-cleaving enzyme as an NEM-inhibitable metalloproteinase of the ADAM family ( Figure 2E through 2G and supplemental materials) . Finally, both adhesion of activated platelets to U937 cells and adhesion of U937 cells to HUVECs were almost completely abolished by staurosporine treatment ( Figure  2H and 2I) .
For further details, see the supplemental materials.
Discussion
We demonstrate that PSGL-1 is completely downmodulated in apoptotic monocytes, unlike the partial reduction observed in response to cell activation. 3 The mechanism underlying 
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the depletion of PSGL-1 on monocytic cells involved primarily proteolytic shedding by an NEM-inhibitable metalloproteinase of the ADAM family. Apoptosis-related PSGL-1 downmodulation resulted in a complete loss of PSGL-1-dependent cell functions (platelet-leukocyte and leukocyte-endothelial cell interactions). These findings have several important physiological and pathophysiological implications. Microparticle-associated, blood-borne TF is incorporated into growing thrombi via PSGL-1 and contributes to thrombus propagation. 2 Thus, downmodulation of this molecule during the apoptotic process may serve as a protective molecular switch to alter this function of microparticles. Phagocytosis of circulating apoptotic cells by the reticulo-endothelial system occurs devoid of coincidental inflammation. One might hypothesize that downmodulation of PSGL-1 in apoptotic monocytes serves to prevent ectopic clearance of these cells in the peripheral vasculature, thus preventing local inflammatory responses. 7 Similarly, the load of platelet-derived mitogenic and inflammatory mediators 8 would be reduced markedly, when activated platelets cannot adhere to PSGL-1-depleted apoptotic monocytes.
